Optimizing Joint Health in Hemophilia

Slides:

Advertisements

Similar presentations

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the United States.

Advertisements

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.

Clinical Trials in IBD.

Psoriatic Arthritis.

A Review of the Critical Role of Imaging in Primary Liver Malignancy

Why Gene Therapy for Hemophilia?

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the United States.

T-Cell Exhaustion: Can We Overcome It in Cancer?

Advances in Managing Inhibitors in Patients With Hemophilia A

5 Things NPs and PAs Need to Know About Tardive Dyskinesia

Progression After Cancer Immunotherapy in Advanced NSCLC

COPD Management.

Hemophilia Updates: Incorporating New Concepts Into Practice

Extended Half-life Factor Products in the Management of Hemophilia

Individualizing Prophylaxis in Hemophilia

Hot Topics in Hemophilia Nursing

Advances in Dry Eye.

Mid-Year Hemophilia Update

Induction Chemotherapy for Patients With High-Risk or Secondary AML

Issues in the Management of Hemophilia: A Best Practice Series

The Resurgence of Topical Treatments Across a Spectrum of Psoriasis

Chronic Idiopathic Urticaria

Expanding Treatment Horizons in Head and Neck Cancer: TRK Inhibitors

Tailoring Hemophilia Prophylaxis Therapy

Asthma and Atopic Comorbidities

The Evolving Role of Immunotherapy in NSCLC

Optimizing Management of Advanced Bladder Cancer

Addressing Challenges in Factor VIII Inhibitors in Children With Hemophilia.

Postpartum Depression

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.

Individualizing Factor Replacement Therapy for Patients With Hemophilia.

Evaluating Next-Generation BTK Inhibitors

Issues in the Management of Hemophilia: A Best Practice Series

Hyperhidrosis Is Burdensome!

Gene Therapy: Past, Present, and Future

Emerging Atopic Dermatitis Treatments:

Ask the Experts.

Immunotherapy for cSCC

Perspectives on the Impact of Inflammation in OA

Optimizing Frontline Care for Older Patients With Multiple Myeloma

Battling Constipation

New Recommendations on How to Stage Hidradenitis Suppurativa

When Is Biologic Therapy Appropriate for HS?

Parkinson Disease Psychosis

Multidisciplinary Approaches to Managing Hemophilia

Prophylaxis Strategies in Hereditary Angioedema Weighing the Evidence

Immune Checkpoint Inhibitors in Lung Cancer

Advancing Patient Care in RA

CMV in the HSCT Recipient

Guide to Atopic Dermatitis

Expanding the Horizons in Hereditary Angioedema

Extended Half-life Factor Products in the Management of Hemophilia

Patient Questions and Expert Answers in Psoriasis:

Current Challenges in Managing Hemophilia

Etiology and Incidence Pathophysiology Hemophilia is due to a defect in thrombin generation on the platelet surface.

Updates in RA, PsA, and Biosimilars

Novel Concepts in the Management of RCC

Improving Overall Health

The Nurse View: Spotlight on Immune Checkpoint Inhibitors in Advanced Lung Cancer.

Getting PPG Under Control

Optimizing Outcomes in mRCC: Finding the Balance of Immune Inhibition

This program will include a discussion of off-label treatment or use of investigational agents not approved by the FDA for use in the US, and data that.

HAE Prophylaxis.

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.

Optimizing Treatment of Refractory Gout

Immune Checkpoint Inhibitors in Lung Cancer

Examining the Role of Pharmacokinetics in Hemophilia

Foundations of Asthma.

Motor Fluctuations in PD

Presentation transcript:

Optimizing Joint Health in Hemophilia

This program will include a discussion of investigational agents not approved by the FDA for use in the United States.

Introduction

Prophylaxis Studies and Joint Health

Challenges to Prophylaxis

Introducing Prophylaxis

Inhibitors

Discussing Prophylaxis Risk With Patients

Overview of EHL Factor Concentrates

Choosing Factor Concentrates

Monitoring Response

Concerns With Prophylaxis

Is It Possible to Stop Prophylaxis?

Functional Assessment Tools

Objective Assessment: Imaging

Global Implications

Concluding Remarks

Abbreviations

Abbreviations (cont)